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CD44 is the major surface hyaluronan (HA) receptor implicated in intercellular and cell-
matrix adhesion, cell migration and signaling. It is a transmembrane, highly glycosylated
protein with several isoforms resulting from alternative gene splicing. The CD44 molecule
consists of several domains serving different functions: the N-terminal extracellular
domain, the stem region, the transmembrane domain and the C-terminal tail. In
the nervous system, CD44 expression occurs in both glial and neuronal cells. The
role of CD44 in the physiology and pathology of the nervous system is not entirely
understood, however, there exists evidence suggesting it might be involved in the axon
guidance, cytoplasmic Ca2+ clearance, dendritic arborization, synaptic transmission,
epileptogenesis, oligodendrocyte and astrocyte differentiation, post-traumatic brain
repair and brain tumour development.
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Introduction
CD44 is a transmembrane glycoprotein mediating cell responses to the extracellular
microenvironment. Also known as the hermes antigen, Pgp1, MDU3 and Inlu-related p80
glycoprotein, it was first described as a surface molecule present in lymphocytes, thymocytes
and granulocytes (Dalchau et al., 1980), and later recognized as a novel human erythrocyte
cell surface antigen, lymphocyte homing receptor, and leukocyte surface glycoprotein
(Stefanová et al., 1989). Today, CD44 is being described as an adhesion molecule expressed
in various cell types, and an important participant in a number of signaling pathways. The
present review summarizes the current knowledge on CD44 expression and function in the
nervous system.
Structure
CD44 molecule consists of several functional domains. The N-terminal extracellular domain
contains motifs serving as docking sites for various ligands—primarily hyaluronan (HA), but
also extracellular matrix (ECM) glycoproteins and proteoglycans, growth factors, cytokines
and matrix metalloproteinases (Figure 1; Yu and Stamenkovic, 1999; Ponta et al., 2003).
The aminoterminal domain of CD44 is separated from the plasma membrane by a short
stem structure with proteolytic cleavage sites for such metalloproteinases as disintegrin,
metalloproteinase domain-containing proteins 10 and 17 (ADAM-10 and ADAM-17) or
membrane type 1-matrix metalloproteinase (MT1–MMP; Okamoto et al., 1999; Nagano and
Saya, 2004). The cleavage of CD44 triggers the release of cells bound to HA—a process important
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FIGURE 1 | CD44 protein structure and signaling. CD44 is a
transmembrane molecule composed of several domains. The N-terminal
extracellular domain can bind various ligands, including hyaluronan
(HA), extracellular matrix (ECM) glycoproteins and proteoglycans,
growth factors, cytokines and matrix metalloproteinases. In result of
the proteolytic cleavage within the stem region, the extracellular
domain is released into the extracellular space. The transmembrane
domain anchors and stabilises the molecule in the plasma membrane.
The cytoplasmic domain is responsible for signal transduction through
binding to different molecules, including cytoskeleton components,
kinases and activators of small Rho GTPases (GEFs-guanine nucleotide
exchange factors).
in the regulation of cell migration. Notably, the stem region is the
variable portion of the protein due to the alternative splicing and
insertion of exons 6–15. The C-terminal cytoplasmic tail region
plays a crucial role in the CD44 involvement in intracellular
signal transduction. It has been shown that it binds to cytoskeletal
elements such as ankyrin, the ERM proteins: ezrin, radixin,
and moesin, and moesin-ezrin-radixin-like protein (MERLIN;
Martin et al., 2003), it also interacts with signaling molecules,
namely members of Src family kinases (SFKs) Src, Lck, Fyn and
Lyn (Ponta et al., 2003), and activators of small Rho GTPases
(Bourguignon et al., 2005). In addition, the cytoplasmic tail
of CD44 may be cleaved off by γ-secretase and translocated
to the cell nucleus, where it acts as a transcriptional regulator
(Nagano and Saya, 2004).
The human gene for CD44 consists of 20 exons and is located
in the 11p13 locus (Thorne et al., 2004). The most common
form of CD44, also called standard CD44 (CD44s), is encoded
by exons 1–5, 16–18 and 20. There also exists a large number
of CD44 variants (CD44v), generated by extensive alternative
splicing and containing the ‘‘standard’’ exons with a combination
of exons 6–15 (Ponta et al., 2003). The predominant CD44
isoform expressed in the nervous system is the standard form
(Sretavan et al., 1994; Jones et al., 2000; Bouvier-Labit et al.,
2002), although the presence of CD44 splice variants has been
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demonstrated in normal human brain tissue (Kaaijk et al., 1997),
as well as in certain primary tumours of the brain and peripheral
nerve (Kaaijk et al., 1995; Sherman et al., 1997; Resnick et al.,
1999).
Expression and Activation in the Nervous
System
Originally, CD44 expression was reported to take place
predominantly in the white matter of the human brain
(McKenzie et al., 1982; Bignami and Dahl, 1986; Cruz et al.,
1986). Likewise, further studies have shown that the source of
CD44 protein was glial cells, in particular astrocytes (Girgrah
et al., 1991; Vogel et al., 1992). In vitro studies with the use
of primary cell cultures from human foetal and adult brain
have evidenced the expression of CD44 in astrocytes and
oligodendrocytes (Moretto et al., 1993; Bouvier-Labit et al.,
2002). The subsequent analysis of developing brain has identified
CD44 as a marker for astrocyte-restricted precursor cells
(ARPs) committed to give rise to astrocytes in vitro and in
vivo, in both rodent and human tissue (Liu et al., 2004). In
mouse cerebellum, CD44 expression was observed not only
in astrocyte precursor cells, but also in neural stem cells and
oligodendrocyte precursor cells (OPCs) at early postnatal stages
(Naruse et al., 2013). CD44 expression in glial cells has been
further demonstrated by studies examining the role of this
molecule in the Schwann cells in developing nerves (Sherman
et al., 2000) and at the neuromuscular junction of the adult rat
skeletal muscle (Gorlewicz et al., 2009). The immunostaining
of surgical specimens of temporal cortex and hippocampus
for CD44 revealed astrocyte diversity in the human brain
in terms of CD44 expression (Sosunov et al., 2014). High
expression of CD44 has been observed in astrocytes with long,
unbranched processes and ‘‘fibrous’’-like astrocytes, whereas the
‘‘protoplasmic’’ astrocytes, which display a ‘‘bushy’’ morphology,
exhibit no CD44 expression. Likewise, during development,
CD44 expression was limited specifically to Bergmann glia and
fibrous astrocytes among three types of astrocytes in cerebellum
(Naruse et al., 2013). Interestingly, the expression of CD44 in
astrocytes was shut off during postnatal development of the
cerebellum.
Although the number of reports point to glial expression
of CD44 in the nervous system, and describe adult neurons
generally as CD44-negative cells (Vogel et al., 1992; Akiyama
et al., 1993; Jones et al., 2000), the neuronal expression has
also been observed. Expression of different splice variants of
CD44, namely CD44v4, CD44v5 and CD44v10, in neurons
(axonal membranes and cytoplasm) of the cerebral cortex,
putamen, thalamus, hippocampus, cerebellum and spinal cord,
in addition to the expression of CD44s in the white matter
astrocytes, has been found in human brain sections (Kaaijk
et al., 1997). It has also been shown that the embryonic optic
chiasm neurons expressed the standard isoform of CD44 protein
(Sretavan et al., 1994), and that strong upregulation of CD44
took place in axotomised facial motoneurons, but not in the
gray matter astrocytes (Jones et al., 1997). In yet another study,
the cellular location of CD44 in the brain tissue in seven
different brain lesion models has been investigated (Jones et al.,
2000). The results demonstrated an inducible expression of
CD44 in cholinergic neurons of the forebrain, brainstem and
spinal cord post distant axotomy, as opposed to its upregulation
in astrocytes and other non-neuronal cell types following a
more severe trauma involving local disruption of the blood-
brain barrier. The antigen has been found in the cell bodies,
dendrites and axons of neurons. CD44 immunoreactivity has
also been detected in the dentate gyrus inner molecular layer
(IML) of the mouse hippocampus after pilocarpine-induced
status epilepticus (SE), where it coincided with early mossy
fiber sprouting (MFS; Borges et al., 2004). Recently, CD44
mRNA has been detected in the neurons of striatum, extended
amygdala and certain hypothalamic, cortical and hippocampal
regions of non-stimulated brain (Glezer et al., 2009), as well
as in the central respiratory control system (ventral respiratory
group—VRG) within the brain stem (Matzke et al., 2007). CD44
expression was also detected in developing cerebellar Purkinje
and granule neurons, but was limited to granule neurons in
the adult cerebellum (Naruse et al., 2013). The expression
of CD44 protein in pyramidal neurons of rat hippocampus
and cortex is also developmentally regulated (Skupien et al.,
2014). It increases postnatally, peaks around day P10 and
then decreases. Notably, electron microscopy analysis revealed
the dendritic localization of CD44 immunostaining within
the pyramidal neurons of the developing hippocampus. There
can be several causes for the apparent discrepancies among
the studies describing expression of CD44 in neurons and
glia. First, the CD44 expression appears to strongly depend
on the developmental stage, especially in neurons. In fact,
the studies claiming neurons to be CD44-negative were done
mainly in the adult brain (Akiyama et al., 1993; Jones et al.,
2000). The discrepancies may result also form differences
in sensitivity of detection methods, and the differences in
CD44 expression levels in glia (higher expression) and neurons
(lower expression). In addition, since CD44 is a subject to
extracellular and intramembrane proteolysis, the antibodies
against its N-terminus may fail to detect the molecule in
cells in which the rate of proteolytic processing is high. Such
differences in the CD44 proteolysis, however, remain to be
investigated.
Biological Function in the Nervous System
The main function ascribed to CD44 is acting as a receptor for
HA—the key component of ECM in the brain playing a crucial
role in many physiological and pathological processes, such as
the neuronal development, synaptic plasticity (e.g., learning and
memory), epileptogenesis, response to injury, neurodegeneration
and brain tumour invasion (Kochlamazashvili et al., 2010;
Wlodarczyk et al., 2011). The neuronal function of hyaluronic
acid receptors, particularly CD44, in the nervous system remains
to be elucidated, although there exists evidence that, among
other processes, CD44 might be involved in the axon guidance
during neuronal development (Figure 2). In vitro studies
indicated that CD44 had an inhibitory effect on embryonic
retinal axon growth (Sretavan et al., 1994), while experiments
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FIGURE 2 | Functions of CD44 in the nervous system.
using specific anti-CD44 blocking antibodies demonstrated
that the functional CD44 molecule in chiasmatic neurons was
essential for axon crossing and axon divergence at the mouse
optic chiasm (Lin and Chan, 2003). Furthermore, it appears
that CD44 participates in the extension of axons from retinal
ganglion cells growing on a laminin substrate (Ries et al.,
2007).
Recently, a novel signaling pathway has been described in
pyramidal neurons of the hippocampus and cerebral cortex,
involving CD44 and Src tyrosine kinase-induced cascade,
regulating Golgi apparatus morphology and dendritic tree
arborization (Skupien et al., 2014). It was shown that the loss
of CD44 resulted in an increase in the complexity of dendritic
arbors in hippocampal neurons cultured in vitro, and in cortical
neurons electroporated in vivo. Moreover, the knockdown of
CD44 resulted in structural alteration of the Golgi apparatus,
an organelle that is essential for mediating dendritic polarity,
growth, and maintenance. Additionally, CD44 interacted with
Src kinase in the brain, and the activation of both c-Src and its
main substrate, focal adhesion kinase (FAK), was decreased upon
CD44 knockdown.
The similar signaling pathway, involving CD44 and plasma
membrane Ca2+ ATPase (PMCA), has been described in
sensory neurons (Ghosh et al., 2011). The proposed molecular
mechanism envisages PMCA as a point of cross-talk enabling
the interaction of ECM and CD44, which regulates the
Ca2+ signaling through the activation of SFKs (Src family
kinases: Lck, Fyn) and FAK cascade. Since Ca2+ clearance
from the neuronal cytoplasm regulates a number of Ca2+-
dependent processes in neurons, including excitability, plasticity
and neurotransmitter release, it appears that CD44 might be
involved in all the above processes. Moreover, hyaluronic
acid has been implicated in hippocampal synaptic plasticity
by modulating postsynaptic L-type voltage-dependent Ca2+
channels (L-VDCCs; Kochlamazashvili et al., 2010). On the
other hand, it has been demonstrated that activity of neuronal
L-VDCCs is regulated by phosphorylation of its α1c subunit
by Src kinase (Bence-Hanulec et al., 2000; Gui et al., 2006).
It would be interesting to investigate whether regulation of
Src activity by CD44 can be involved in L-VDCCs-dependent
synaptic plasticity.
In the nervous system and other tissues, CD44 can act as a
co-receptor for receptor tyrosine kinases (RTKs) and serve as
a platform for signaling molecule assembling. For instance, in
the peripheral nervous system, CD44 enhances the neuregulin
signaling by mediating the ErbB receptor heterodimerization
in Schwann cells of the developing peripheral nerves (Sherman
et al., 2000). In the adult rat nerve-muscle synapse, CD44 present
in terminal Schwann cells has been shown to bind to ErbB3
receptors and to be involved in the neuromuscular junction
plasticity (Gorlewicz et al., 2009). Moreover, the CD44v6
isoform can act as a co-receptor for c-Met in vitro (Orian-
Rousseau et al., 2002). The CD44-c-Met interaction during
embryogenesis has been further demonstrated by in vivo studies
(Matzke et al., 2007) showing that c-Met is haploinsufficient
in the CD44−/− background. The CD44−/− c-Met+/− mice
die at birth due to a breathing defect caused by impaired
synaptic transmission in the respiratory rhythm generating
network, and alterations in the phrenic nerve, while c-Met
−/−CD44+/+, and CD44−/− c-Met+/+ mice develop normally
and do not exhibit phenotypic abnormalities. The above results
suggest that CD44 and c-Met are involved in synaptogenesis
and axon myelination in the central and peripheral nervous
systems.
It has been shown that CD44-deficient mice were born at
the Mendelian ratio without any obvious developmental or
neurological defects (Schmits et al., 1997). However, recently,
Raber et al, applied a battery of behavioral and cognitive
tests to determine if CD44-null mice display cognitive or
other neurological disturbances (Raber et al., 2014). The
results support an important role for CD44 in locomotor
and sensorimotor functions, and in spatial memory retention,
but do not specify whether these effects are due to the
lack of CD44 in neurons or in glia. Given that CD44 is
expressed in neural stem cells implicated in spatial memory
(Oishi and Ito-Dufros, 2006; Deng et al., 2009; Naruse et al.,
2013) the observed deficits can indicate that CD44 depletion
in mice influences adult neurogenesis which in turn affects
memory.
Interestingly, Matzke et al. (2007) have shown that the
glutamatergic synaptic excitation in CD44 knockout mice
was strongly reduced, while no change was detected in the
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glycinergic and GABAergic synaptic inhibition or in the
overall synaptic activity of pre-Bötzinger complex neurons
within the brain stem (Matzke et al., 2007). The above
observations seem to indicate a potential role of CD44 in
synaptic transmission, yet this requires more in-depth research.
The absence of overt neurological defects in CD44 knockout
mice might be explained by efficient compensation by another
protein, all the more so since HA-mediated motility receptor
(RHAMM) and intercellular adhesion molecule-1 (ICAM-1)
have previously been shown to take over the CD44 role in
the CD44 knockout mice (Nedvetzki et al., 2004; Olaku et al.,
2011).
Although, the expression of CD44 in astrocytes has been
described, the function of the interaction of HA and its
receptor in these cells is poorly understood. It has been
shown that interaction of hyaluronic acid with CD44 induce
Rac 1-dependent PKNγ (protein kinase N-γ) activity which,
in turn up-regulates the phosphorylation of the cytoskeletal
protein, cortactin. This HA/CD44 interaction with Rac1-
PKNγ leads to cytoskeleton activation and enhanced astrocyte
migration (Bourguignon et al., 2007). Similarly, in neural
precursor cells, overexpression of CD44 protein significantly
enhanced the in vitro and in vivo trans-endothelial migration
of these cells (Deboux et al., 2013). Moreover, it was shown
that CD44 overexpression in glial precursor cells inhibits
differentiation towards oligodendrocytes and increases the
differentiation into astrocytes (Liu et al., 2004). Accordingly, a
high molecular weight form of HA was also shown to inhibit
maturation of OPCs into myelin-forming cells (Back et al.,
2005).
Association with the Nervous System
Pathologies
The limited data from descriptive studies, indicating a
widespread upregulation of CD44 expression in neurons
and non-neuronal cells post brain injury, suggest an important
role of this cell surface glycoprotein in the neuronal, glial and
leukocyte response to trauma and in the nervous system repair
(Jones et al., 2000; Shin et al., 2005). However, the molecular
mechanisms underlying the above processes remain to be
elucidated.
Few studies conducted to investigate the CD44 role in
epileptogenesis have provided inconsistent results. It has
been observed that CD44 was strongly upregulated in the
dentate IML 3 days post pilocarpine-induced SE in mice,
then it declined over the next 4 weeks (Borges et al.,
2004). CD44 appeared to be one of the earliest proteins
upregulated in the IML, which coincided with early MFS. On
the other hand, repeated kainate injections did not induce
any changes in the CD44 expression in the IML, which also
correlated with MFS absence in the mice hippocampus. In
view of the above, it has been hypothesized that CD44 was
involved in the response to axon terminal degeneration and/or
neuronal reorganization preceding MFS. Contrary to the above
observations, studies on CD44 expression in an in vitro model
of MFS have shown that high CD44 expression in the molecular
layer coincided with minimal MFS, and that reduced CD44
expression/function following the kainic acid (KA) treatment or
use of blocking antibodies was associated with increased MFS
(Bausch, 2006). The time course of KA-induced decrease in
CD44 expression corresponded with the temporal progression
of KA-induced MFS in hippocampal slice cultures, suggesting
that reduced CD44 expression might contribute to MFS. HA
has been also implicated in epileptogenesis. Studies with the
use of microelectrode array recording and Ca2+ imaging in
hippocampal neurons cultured in vitro revealed that enzymatic
removal of HA by hyaluronidase induced epileptiform activity
in neuronal network (Vedunova et al., 2013). Additionally,
mice deficient in HA synthase (HAS) genes, especially Has 3
knock-outs, exhibit epileptic phenotype along with a pronounced
reduction in the level of tissue HA (Arranz et al., 2014).
Recently, it was shown that the silencing of CD44 expression
during the early development of neuronal cells exerted a
significant protective effect on young neurons that were exposed
to subtoxic conditions, by preventing dendritic shortening
induced by glutamate exposure (Skupien et al., 2014). Therefore,
CD44 might be a novel therapeutic target in neurological
disorders in which alterations in dendritic tree arborization have
been observed.
One of a few studies with the use of CD44 knockout mice
has provided evidence for the potential role of CD44 in the
response to ischaemia in brain tissue (Wang et al., 2002).
These findings indicated that CD44 deficiency in mice protected
their brain from cerebral ischemia injury, and it has been
suggested that this effect might be associated with selective
reduction in inflammatory cytokines, for instance interleukin-
1b. These results are further supported by studies showing
that CD44 expression in activated microglia can be involved in
the pathogenesis of neuroinflamatory diseases. Up-regulation of
CD44 expression in microglia/macrophages were observed after
transient or permanent forebrain ischemia in rats (Wang et al.,
2001; Kang et al., 2008), in experimental cryolesions, a model
for rat brain injury (Shin et al., 2005) and in mouse model of
amyotrophic lateral sclerosis (ALS; Matsumoto et al., 2012).
Increased expression of CD44 and HA accumulation has
also been observed in the brain white matter of patients with
multiple sclerosis (MS), as compared with the normal brain tissue
(Girgrah et al., 1991; Back et al., 2005). Consistently, elevated
levels of both CD44 and HA has been detected in areas where
there was loss of myelin, in the acute and chronic lesions in
mice with experimental autoimmune encephalomyelitis (EAE),
a murine model of MS (Back et al., 2005). Transgenic mice
that overexpressed CD44 under the control of a myelin-specific
promoter had widespread CNS dysmyelination and progressive
demyelination that occurred in the absence of an inflammatory
response (Tuohy et al., 2004). These findings provide strong
evidence that CD44 proteins expressed by oligodendrocytes
and Schwann cells, play a role in promoting demyelination.
Moreover, HA staining intensity correlated with the levels
of CD44 in CD44-overexpressing mice, indicating that HA
accumulates in demyelinating CNS lesions as a result, at least
in part, of elevated CD44 expression by glial cells (Back et al.,
2005). HA inhibits remyelination and OPCs maturation after
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chemical demyelination of mouse white matter (Back et al.,
2005) but, in vitro studies showed that blocked maturation
of oligodendrocytes depends on HA interaction with Toll-
like receptor 2 (TLR2) rather than with CD44 expressed by
OPCs (Sloane et al., 2010). CD44 expression was strongly
induced by activated astrocytes surrounding the demyelinated
lesions suggesting that CD44 may play a role in facilitating
inflammatory responses during reactive gliosis (Girgrah et al.,
1991; Haegel et al., 1993). In MS the interactions between
astrocytes and lymphocytes occurs during the entry of activated
lymphocytes into the CNS, and in the sites of lesions. It
was shown that CD44 is involved in direct contacts between
T-cells and astrocytes in EAE mice (Haegel et al., 1993).
Recently, an increased EAE disease severity and inflammation
was demonstrated in CD44-KO mice (Flynn et al., 2013). CD44-
deficient mice with EAE had more pro-inflammatory T-cell
profile and increased permeability of the brain-blood barrier
(BBB) than WT controls. The data suggest that CD44 acts
as a negative regulator of inflammation with roles in T-cell
differentiation, adhesion and trans-endothelial migration, and
BBB permeability.
Protoplasmic astrocytes in patients with Alexander disease,
a primary disorder of astrocytes, caused by heterozygous
mutations in GFAP (glial fibrillary acidic protein), convert to
reactive cells that lost their bushy-like morphology and become
multinucleated and hypertrophic (Sosunov et al., 2013). This
phenotypic conversion is accompanied by acquiring of CD44 by
normally CD44-negative protoplasmic astrocytes of gray matter
suggesting that CD44 can play a role in this process e.g., by
regulation of changes in astrocyte shape.White matter of patients
with vanishing white matter disease, that is associated with
maturation defect of astrocytes and oligodendrocytes, is enriched
in CD44-expressing astrocyte precursor cells and accumulates
HA (Bugiani et al., 2013). Accumulation of HA synthesized
by CD44-positive reactive astrocytes was also observed during
chronic human neonatal white matter injury (Buser et al., 2012;
Back and Rosenberg, 2014).
Chronically elevated CD44 expression and HA accumulation
occur in non-human primate CNS with normal aging as a
result of age-related astrogliosis and are linked to the aberrant
accumulation of OPCs (Cargill et al., 2012). CD44 expression is
also highly and persistently upregulated by astrocytes in brains of
patients with Alzheimer’s disease (AD; Akiyama et al., 1993).
Several studies have demonstrated the correlation between
high CD44 expression and poor prognosis in patients with brain
tumour. CD44s and CD44v are frequently expressed in primary
brain tumours and seem to be essential for the invasive growth
of various CNS-derived tumour cell types in vitro and in vivo
(Kuppner et al., 1992; Nagasaka et al., 1995; Sherman et al., 1997;
Breyer et al., 2000; Monaghan et al., 2000; Pusch et al., 2010).
The precise mechanism of CD44 action in the development and
invasiveness of nervous system tumours has not been elucidated
to date. In glioblastoma multiforme (GBM), the most aggressive
brain tumour, CD44 inhibits the activation of the mammalian
equivalent of Hippo signaling pathway and plays a key role in
regulating the stress and apoptotic responses of human GBM
cells (Xu et al., 2010). In addition, it has been found that a
subset of human GBM cases showed high expression of CD44
in brain tumour stem-like cells (BTSC), and that the growth of
these tumours might depend on CD44v6/AKT signaling pathway
(Jijiwa et al., 2011). Su and colleagues have demonstrated that
CD44 overexpression was induced by the Src kinase activity in
malignant peripheral nerve sheath tumour (MPNST) cells, and
that it contributed to tumour invasiveness (Su et al., 2003). By
contrast, in neuroblastomas, CD44 expression is often low in
advanced tumours (Combaret et al., 1997; Gross et al., 1997,
2000; Kramer et al., 1997). Shtivelman and Bishop (1991) have
shown that several upstream cis-acting elements contribute to the
downregulation of CD44 gene expression in neuroblastoma cells
(Shtivelman and Bishop, 1991).
Overall, it appears that both the overexpression and lack
of expression of CD44 might be involved in the development
and invasiveness of various brain tumour types. The results of
the performed studies are consistent with the hypothesis put
forward by Herrlich and colleagues, stating that CD44 might
play a dual role in cancer pathogenesis, acting as either an
oncogene or a tumour-suppressing factor (Herrlich et al., 2000).
By binding to growth factors and presenting them to their
receptors, CD44 might be involved in the activation of tumour-
promoting signaling pathways. On the other hand, in certain
conditions, binding of HA might lead to the recruitment of
tumour suppressor proteins (e.g., merlin) into the cytoplasmic
tail of CD44 and result in cell growth arrest. Clearly, the
posed hypothesis is elegant in its attempt to explain the dual
role of CD44 in tumorigenesis. Nevertheless, its confirmation
requires further research, for instance the identification of
individual signaling cascades involved in the above-suggested
mechanisms—particularly in the brain tissue.
In conclusion, there is growing evidence that the previously
underappreciated CD44 molecule might be a key signal
transducer in neurons, where it can act as a c-Met co-receptor
to regulate synaptic transmission or through the activation
of Src-dependent signaling pathways to influence dendritic
arborization and calcium ions clearance. Additionally, CD44 can
also modulate many other processes important for neuronal
functions summarized in Figure 2, i.e., memory retention and
axonal growth, but the exact cellular mechanisms of CD44
action in these phenomena are not discovered yet. One can
expect that, at least some of the neuronal functions exerted
by CD44, depend on HA binding but still the experimental
evidences consistent with this notion are missing. In glial cells,
unlike in neurons, binding of HA to CD44 receptor was shown
to play an important roles in both physiological (myelination
and oligodendrocyte maturation) and pathological (astrogliosis,
demyelination) processes. However, except of the well-defined
signaling cascade that include CD44/HA-dependent activation of
small RhoGTPase Rac1 and PKNγ and subsequent cytoskeletal
rearrangement in migrating astrocytes, CD44-related cellular
mechanisms in glial cells (astrogliosis, microglia activation,
oligodendrocyte and astrocyte maturation, see Figure 2) still
remain to be elucidated. Furthermore, explanation of precise
molecular mechanisms of CD44 action might potentially form
basis for novel therapeutic interventions in a number of CNS
disorders.
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